You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.
The effort is focused on building an atlas of immune cell types found across a range of Asian population groups as part of the Human Cell Atlas project.
A*STAR and Tan Tock Seng Hospital developed the test, which is the first diagnostic to be deployed in the country's hospitals since the outbreak began in December.
Researchers in Singapore found fewer genetic alterations in tumors from East Asians than Europeans and identified a gene expression subtype specific to East Asians.
For the first phase of the SG10K project, researchers sequenced thousands of Chinese, Malay, or Indian individuals from Singapore, uncovering new variants and population insights.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.
One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to develop a point-of-care diagnostic platform for infectious disease.
Nobel laureate Sydney Brenner has died at the age of 92, BBC News reports.
The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.